Long-term treatment of neuropathic pain with a 5% lidocaine medicated plaster

被引:34
|
作者
Wilhelm, Ilca Ricarda [1 ]
Tzabazis, Alexander [1 ]
Likar, Rudolf [2 ]
Sittl, Reinhard [1 ]
Griessinger, Norbert [1 ]
机构
[1] Univ Hosp Erlangen, Dept Anaesthesiol, D-91054 Erlangen, Germany
[2] Landeskrankenhaus Klagenfurt, Dept Anaesthesiol & Intens Care, Klagenfurt, Austria
关键词
central regional pain syndromes; lidocaine; lidoderm; local anaesthetics; peripheral nervous system diseases; postherpetic neuralgia; POSTHERPETIC NEURALGIA; PATCH; 5-PERCENT; DOUBLE-BLIND; EFFICACY; TOLERABILITY; RELIEVES; SCALE;
D O I
10.1097/EJA.0b013e328330e989
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background and objective The 5% lidocaine medicated plaster is a topical treatment for peripheral neuropathic pain symptoms (e.g. burning, shooting and stabbing pain) and is registered for the treatment of postherpetic neuralgia. This study examined the efficacy and tolerability of long-term treatment with the 5% lidocaine medicated plaster in patients with localized neuropathic pain conditions. Methods Twenty patients with localized neuropathic pain [postoperative neuropathic pain (n = 14); complex regional pain syndrome (n = 2); and postherpetic neuralgia (n = 4)], who had been successfully treated with 5% lidocaine medicated plaster, were followed up by telephone interview after 3 and 5 years. Questions were related to the efficacy, development of tolerance, tolerability, wear time and comfort of the plaster. Results At 3 years, 10 out of 20 (50%) initial responders were still using the plasters with no decline in analgesic efficacy. After 5 years, eight of the original 20 responders (40%) maintained treatment and continued to experience effective pain relief. The 12 responders who discontinued treatment did so because they no longer required analgesic therapy (n = 4); their health insurer refused to fund treatment (n = 2); they were lost to follow-up (n = 1); or had died from an illness unrelated to plaster treatment (n = 5). No patient discontinued because of inadequate analgesia or intolerable side effects. Reversible erythema occurred in two patients wearing the plaster for more than 16 h. There were no systemic side effects. Conclusion The 5% lidocaine medicated plaster provides sustained pain relief over long-term treatment in patients with neuropathic pain of various causes and is well tolerated. Eur J Anaesthesiol 27:169-173 (c) 2010 European Society of Anaesthesiology.
引用
收藏
页码:169 / 173
页数:5
相关论文
共 50 条
  • [21] Reduction of painful area as new possible therapeutic target in post-herpetic neuropathic pain treated with 5% lidocaine medicated plaster: a case series
    Casale, Roberto
    Di Matteo, Maria
    Minella, Cristina E.
    Fanelli, Guido
    Allegri, Massimo
    JOURNAL OF PAIN RESEARCH, 2014, 7 : 353 - 357
  • [22] Safety and efficacy outcomes of long-term treatment up to 4 years with 5% lidocaine medicated plaster in patients with post-herpetic neuralgia
    Sabatowski, Rainer
    Hans, Guy
    Tacken, Ingrid
    Kapanadze, Sofia
    Buchheister, Bettina
    Baron, Ralf
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (08) : 1337 - 1346
  • [23] 5% Lidocaine Medicated Plaster for the Treatment of Postherpetic Neuralgia: A Review of the Clinical Safety and Tolerability
    Navez M.L.
    Monella C.
    Bösl I.
    Sommer D.
    Delorme C.
    Pain and Therapy, 2015, 4 (1) : 1 - 15
  • [24] Lidocaine 5%-medicated plaster (Versatis) for localised neuropathic pain: results of a multicentre evaluation of use in children and adolescents
    Goddard, John M.
    Reaney, Rebecca L.
    BRITISH JOURNAL OF PAIN, 2018, 12 (03) : 189 - 193
  • [25] Lidocaine medicated plaster, an additional potential treatment option for localized post-surgical neuropathic pain: efficacy and safety results of a randomized, placebo-controlled trial
    Palladini, Mariana
    Boesl, Irmgard
    Koenig, Simone
    Buchheister, Bettina
    Attal, Nadine
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (05) : 757 - 766
  • [26] Comparative Benefit-Risk Assessment for Lidocaine 700 mg Medicated Plaster and Pregabalin in Peripheral Neuropathic Pain Following a Structured Framework Approach
    Sabatschus, Ingo
    Boesl, Irmgard
    Prevoo, Marlou
    Eerdekens, Marieelle
    Spruenken, Arne
    Galm, Oliver
    Forstner, Michael
    PAIN AND THERAPY, 2022, 11 (01) : 73 - 91
  • [27] Effectiveness and safety of 5% lidocaine-medicated plaster on localized neuropathic pain after knee surgery: a randomized, double-blind controlled trial
    Pickering, Gisele
    Voute, Marion
    Macian, Nicolas
    Ganry, Herve
    Pereira, Bruno
    PAIN, 2019, 160 (05) : 1186 - 1195
  • [28] 5% lidocaine medicated plaster in painful diabetic peripheral neuropathy (DPN): a systematic review
    Wolff, Robert F.
    Bala, Malgorzata M.
    Westwood, Marie
    Kessels, Alfons G.
    Kleijnen, Jos
    SWISS MEDICAL WEEKLY, 2010, 140 (21-22) : 297 - 306
  • [29] Post-herpetic neuralgia: 5% lidocaine medicated plaster, pregabalin, or a combination of both? A randomized, open, clinical effectiveness study
    Rehm, Stefanie
    Binder, Andreas
    Baron, Ralf
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (07) : 1607 - 1619
  • [30] Lidocaine 5% Medicated Plaster A Review of its Use in Postherpetic Neuralgia
    Garnock-Jones, Karly P.
    Keating, Gillian M.
    DRUGS, 2009, 69 (15) : 2149 - 2165